Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects

Neurogastroenterology and Motility

Volumn 26, Issue 8, 2014, Pages 1079-1086

  Kessing, B F ^a   Smout, A J P M ^a   Bennink, R J ^a   Kraaijpoel, N ^a   Oors, J M ^a   Bredenoord, A J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 HT4 receptor agonist; Esophagus; Gastric emptying; Gastro esophageal reflux disease; Manometry; PH Monitoring; Prucalopride; Stomach

Indexed keywords

BENZOFURAN DERIVATIVE; PRUCALOPRIDE; SEROTONIN 4 AGONIST;

CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; MANOMETRY; METABOLISM; NORMAL HUMAN; PH; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; STOMACH PH;

BENZOFURANS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GASTRIC ACIDITY DETERMINATION; GASTRIC EMPTYING; GASTROESOPHAGEAL REFLUX; HEALTHY VOLUNTEERS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; SEROTONIN 5-HT4 RECEPTOR AGONISTS;

EID: 84904426438     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12359     Document Type: Article

References (22)

1. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61: 1340-54.
2. Kessing BF, Conchillo JM, Bredenoord AJ, Smout AJPM, Masclee AAM. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 33: 650-61.
3. Bredenoord AJ, Weusten BLAM, Timmer R, Smout AJPM. Gastro-oesophageal reflux of liquids and gas during transient lower oesophageal sphincter relaxations. Neurogastroenterol Motil 2006; 18: 888-93.
4. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43: 2028-33.
5. Frampton JE. Prucalopride. Drugs 2009; 69: 2463-76.
6. Prins NH, van Der Grijn A, Lefebvre RA, Akkermans LM, Schuurkes JA. 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001; 132: 1941-7.
7. Briejer MR, Bosmans JP, Van Daele P, Jurzak M, Heylen L, Leysen JE, Prins NH, Schuurkes JA. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001; 423: 71-83.
8. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682-6.
9. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-60.
10. Wienbeck M, Li Q. Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand J Gastroenterol Suppl 1989; 165: 13-8; discussion 27-28.
11. Gilbert RJ, Dodds WJ, Kahrilas PJ, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331-6.
12. Smout AJ, Bogaard JW, Grade AC, ten Thije OJ, Akkermans LM, Wittebol P. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985; 26: 246-51.
13. Fox M, Menne D, Stutz B, Fried M, Schwizer W. The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment Pharmacol Ther 2006; 24: 1017-27.
14. Tutuian R, Mainie I, Allan R, Hargreaves K, Agrawal A, Freeman J, Gale J, Castell DO. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 2006; 24: 155-62.
15. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 1503-9.
16. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-31.
17. Holloway RH, Boeckxstaens GE, Penagini R, Sifrim D, Smout A, Ruth M. T1229 objective definition and detection of transient lower esophageal relaxation revisited: is there room for improvement? Gastroenterology 2009; 136(5, Supplement 1): A-527.
18. Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJPM. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012; 24(Suppl. 1): 57-65.
19. Conchillo JM, Selimah M, Bredenoord AJ, Samsom M, Smout AJPM. Air swallowing, belching, acid and non-acid reflux in patients with functional dyspepsia. Aliment Pharmacol Ther 2007; 25: 965-71.
20. Bredenoord AJ, Weusten BLAM, Curvers WL, Timmer R, Smout AJPM. Determinants of perception of heartburn and regurgitation. Gut 2006; 55: 313-8.
21. Hemmink GJM, Bredenoord AJ, Weusten BLAM, Monkelbaan JF, Timmer R, Smout AJPM. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: "on" or "off" proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-53.
22. Bredenoord AJ. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. Am J Gastroenterol 2012; 107: 8-15.